News

We’re in the midst of a paradigm shift in biomarker science. | The right biomarker signature can de-risk trials, guide ...
UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.
Gayle Hamilton, director of RBQM for IQVIA’s Digital Trial Management Suite, is an experienced Risk-Based Monitoring project advisor and project lead, with a strong background in clinical ...
With technology/AI taking over administrative and repetitive tasks, human roles will shift towards more strategic, creative, ...
Rakovina Therapeutics Inc. ('Rakovina” or the 'Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next ...
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here. In the ...
Data from NPC and CEVR reveal utilization management is common even when clinical guidelines do not support its use. WASHINGTON, DC, UNITED STATES, July 8, 2025 /EINPresswire.com/ -- New research by ...
MedeAnalytics, a healthcare enterprise data enrichment platform and analytics software-as-a-service (SaaS) leader, and ZeOmega®, the leading population health management organization, today announced ...
Patients with inflammatory bowel disease may be twice as likely to develop rheumatoid arthritis than those without IBD.
The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...